Loading...
•
Sep 30, 2024
•/
DBV Technologies Q3 2024 Earnings Report
DBV Technologies reported financial results for Q3 2024, highlighting a cash balance of $46.4 million and ongoing clinical trial expenses.
Key Takeaways
DBV Technologies reported its Q3 2024 financial results, revealing a cash balance of $46.4 million. The company's operating income was $1.1 million. The company experienced a net loss of $30.4 million, with a basic/diluted net loss per share of $(0.32).
Cash and cash equivalents amounted to $46.4 million as of September 30, 2024.
Operating income for the quarter was $1.1 million.
Net loss for the quarter was $30.4 million, or $(0.32) per share.
The company expects its cash balance to fund operations into Q1 2025.
DBV Technologies
DBV Technologies
Forward Guidance
DBV Technologies anticipates that its cash and cash equivalents will sustain operations into Q1 2025 and intends to seek additional funding for research and development, as well as the potential launch of Viaskin Peanut.
Positive Outlook
- Cash runway expected into Q1 2025.
- Focus on advancing Viaskin Peanut through clinical trials.
- Preparing for potential launch of Viaskin Peanut.
- Committed to transforming the care of food allergic people.
- Ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers and children.
Challenges Ahead
- Substantial doubt about ability to continue as a going concern.
- Company has incurred operating losses and negative cash flows from operations since inception.
- Uncertainty regarding obtaining necessary financing.
- Potential need to scale back operations if financing is not successful.
- Reliance on additional capital to fund operations.